(M2 PressWIRE Via Acquire Media NewsEdge) SmallCapReview.com has been a leading site for information on Small Cap Stocks, Penny Stocks and Microcaps since 1999. Visit http://SmallCapReview.com to sign up for our FREE newsletter.
Audience (Nasdaq: ADNC) $12.22. Announced Thursday after market close its fourth quarter and calendar year2012 financial results.
Revenue for the fourth quarter of 2012 was $38.7 million, compared with $18.0 million for the same period in 2011. As reported under U.S. generally accepted accounting principles (GAAP), fourth quarter 2012 net income was $3.1 million, or $0.14 per diluted share based on weighted average shares outstanding of 22.5 million.
GAAP net income for the fourth quarter of 2012 included a $1.2 million income tax benefit from the release of a valuation allowance against Audience's deferred tax asset. This compares with a GAAP net loss of $5.6 million, or $(5.56) per diluted share based on weighted average shares outstanding of 1.0 million,for the same period in 2011. Gross margin on a GAAP basis for the fourth quarter of 2012 was 53.8% of revenue, compared to 44.5% of revenue for the same period in 2011.
What They Do: Audience is the leader in advanced voice and audio processing for mobile devices.
TeleCommunication Systems (Nasdaq: TSYS) $2.26. Today announced that its map, local search, location services and navigation application, along with software components, are included in the new BlackBerry 10 platform.The TCS-powered maps application ships with the new BlackBerry 10 smartphones and TCS' associated Application Program Interfaces (APIs) are also available for BlackBerry 10 developers. The mapping and navigation solution includes a series of planned updates and innovation to expand the feature set and to enhance the content and user experience.
What They Do: TeleCommunication Systems is a world leader in highly reliable and secure mobile communication technology.
VIVUS (Nasdaq: VVUS) $12.11. Today announced the publication of a study concluding that weight loss resulting from treatment with QsymiaTM (phentermine and topiramate extended-release) capsules CIV led to significant improvements in cholesterol, blood pressure and triglycerides in obese and overweight patients experiencing one or more of these associated conditions. The improvements were significantly greater among patients who lost 10% or more of their starting weight.
"This provides clear evidence that patients with hypertension or high cholesterol treated with Qsymia for one year experienced significant weight loss and clinically meaningful improvements in their underlying cardiovascular risk factors," said Suzanne Oparil, M.D., Director of the Vascular Biology and Hypertension Program, University of Alabama at Birmingham, and an investigator in the study. "The ability to improve underlying risk factors is another reason physicians should proactively discuss the medical treatment of obesity with their patients who have failed lifestyle modification alone."
What They Do: VIVUS is a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health for U.S., Europe and other world markets.
((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to email@example.com)).